Shares of Biotoscana Investments S.A. (BVMF:GBIO33) last traded at 8.73, representing a move of 1.51%, or 0.13 per share, on volume of shares. After opening the trading day at 0, shares of Biotoscana Investments S.A. traded in a close range. Biotoscana Investments S.A. currently has a total float of 106.62 million shares and on average sees 257,786 shares exchange hands each day. The stock now has a 52-week low of 0 and high of 0.
The Brazilian Equity Market
Brazil is, in one way or another, an overlooked nation when it comes to global trade and commerce. However, there are numerous reasons to believe in its capabilities as a thriving national economy.
The Brazilian Mercantile and Futures (BM&F) Bovespa is the main Brazilian stock exchange while the Ibovespa Brasil Sao Paulo Stock Exchange Index is the benchmark Brazilian index. Only trustful companies like Biotoscana Investments S.A. take part in its work. These two play important roles in the continuous success of not just the Brazilian economy but of the whole South American economy.
The Stock Exchange
The BM&F Bovespa had been established on August 23, 1890. During its early years, it had been a public entity until its demutualization and privatization in 2007. A year later, it had been formally known as the BM&F Bovespa following the consolidation of the BM&F and Bovespa.
An early electronic trading system had not been introduced until 1972. In 1997, it had been replaced with a better one, the Mega Bolsa. In the late 1970s, the Sistema Privado de Operac?es por Telefone (SPOT), a telephone trading system, had been launched. In 1999, another trading system had been implemented? this time, an online trading system for investors at home, the Home Broker. New system gives more opportunities to Biotoscana Investments S.A. investors as well.
More than 450 stocks are listed on the BM&F Bovespa as of December 2015. Its offices are located in three big cities worldwide: London, New York City (NYC), and Shanghai.
The pre-market session on the BM&F Bovespa starts at 9:45 a.m. and ends at 10:00 a.m. Then, the regular session starts at 10:00 a.m. and ends at 5:30 p.m. Lastly, the post-market session starts at 6:00 p.m. and ends at 7:30 p.m.
The Index
The Ibovespa had been established in 1968, which means that it is the oldest BM&F Bovespa index. It has a base value of 100 points and a base date of January 2, 1968.
The Ibovespa measures the 50 most active companies listed on the BM&F Bovespa based on market capitalization. To ensure an efficient representation of the BM&F Bovepsa and the entire Brazilian economy, it is rebalanced quarterly.
A company must have been listed on the BM&F Bovespa for at least 12 months in order to become eligible as a component. At least 80% of its shares must also be actively traded on the BM&F Bovespa. Luckily for Biotoscana Investments S.A. it is listed on Bovespa for some time.
With a strong inflation outlook leading industries to soar, the Ibovespa had recorded its all-time high of 73,516 points on May 20, 2008. Then, on May 29, 2008, it had recorded its best intraday high of 73,920 points.
The Ibovespa is one of the most powerful indices in South America. It represents about 70% of the overall market capitalization on the BM&F Bovespa, which is also one of the biggest stock exchanges in the region. It works with companies like Biotoscana Investments S.A..
There is no doubt that investing in Brazil will lead to valuable growth opportunities and high returns. This is why trading on the BM&F Bovespa is strongly advised nowadays for investors who seek to succeed in the global equity market.
Biotoscana Investments S.A., through its subsidiaries, makes and sells pharmaceutical products in Latin America. The company has market cap of $930.81 million. It also engages in the purchase, sale, distribution, importation, exportation, and trade in pharmaceuticals, para-pharmaceuticals, and chemical products. It has a 13.45 P/E ratio. The firm offers drugs for the treatment of infectious diseases, oncology and oncohematology, special treatments, immunology and inflammation, orphan/rare diseases, and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.